179 related articles for article (PubMed ID: 35730256)
21. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
[TBL] [Abstract][Full Text] [Related]
22. IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.
Izquierdo-Garcia JL; Viswanath P; Eriksson P; Cai L; Radoul M; Chaumeil MM; Blough M; Luchman HA; Weiss S; Cairncross JG; Phillips JJ; Pieper RO; Ronen SM
Cancer Res; 2015 Aug; 75(15):2999-3009. PubMed ID: 26045167
[TBL] [Abstract][Full Text] [Related]
23. The heterocyclic compound Tempol inhibits the growth of cancer cells by interfering with glutamine metabolism.
Ye S; Xu P; Huang M; Chen X; Zeng S; Wang Q; Chen J; Li K; Gao W; Liu R; Liu J; Shao Y; Zhang H; Xu Y; Zhang Q; Zhong Z; Wei Z; Wang J; Hao B; Huang W; Liu Q
Cell Death Dis; 2020 May; 11(5):312. PubMed ID: 32366855
[TBL] [Abstract][Full Text] [Related]
24. Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase.
Izquierdo-Garcia JL; Cai LM; Chaumeil MM; Eriksson P; Robinson AE; Pieper RO; Phillips JJ; Ronen SM
PLoS One; 2014; 9(9):e108289. PubMed ID: 25243911
[TBL] [Abstract][Full Text] [Related]
25. NADP+ -dependent IDH1 R132 mutation and its relevance for glioma patient survival.
Baldewpersad Tewarie NM; Burgers IA; Dawood Y; den Boon HC; den Brok MG; Klunder JH; Koopmans KB; Rademaker E; van den Broek HB; van den Bersselaar SM; Witjes JJ; Van Noorden CJ; Atai NA
Med Hypotheses; 2013 Jun; 80(6):728-31. PubMed ID: 23541771
[TBL] [Abstract][Full Text] [Related]
26. Blockade of Glutathione Metabolism in
Tang X; Fu X; Liu Y; Yu D; Cai SJ; Yang C
Mol Cancer Ther; 2020 Jan; 19(1):221-230. PubMed ID: 31548295
[TBL] [Abstract][Full Text] [Related]
27. Mutant IDH1 is required for IDH1 mutated tumor cell growth.
Jin G; Pirozzi CJ; Chen LH; Lopez GY; Duncan CG; Feng J; Spasojevic I; Bigner DD; He Y; Yan H
Oncotarget; 2012 Aug; 3(8):774-82. PubMed ID: 22885298
[TBL] [Abstract][Full Text] [Related]
28. Wild-type IDH1 Knockout Leads to G0/G1 Arrest, Impairs Cancer Cell Proliferation, Altering Glycolysis, and the TCA Cycle in Colon Cancer.
Atalay EB; Senturk S; Kayali HA
Biochem Genet; 2023 Aug; 61(4):1470-1486. PubMed ID: 36633771
[TBL] [Abstract][Full Text] [Related]
29. IDH1 gene transcription is sterol regulated and activated by SREBP-1a and SREBP-2 in human hepatoma HepG2 cells: evidence that IDH1 may regulate lipogenesis in hepatic cells.
Shechter I; Dai P; Huo L; Guan G
J Lipid Res; 2003 Nov; 44(11):2169-80. PubMed ID: 12923220
[TBL] [Abstract][Full Text] [Related]
30. Cloning and characterization of the gene encoding the IDH1 subunit of NAD(+)-dependent isocitrate dehydrogenase from Saccharomyces cerevisiae.
Cupp JR; McAlister-Henn L
J Biol Chem; 1992 Aug; 267(23):16417-23. PubMed ID: 1644826
[TBL] [Abstract][Full Text] [Related]
31. Up-regulated isocitrate dehydrogenase 1 suppresses proliferation, migration and invasion in osteosarcoma: in vitro and in vivo.
Hu X; Liu Y; Qin C; Pan Z; Luo J; Yu A; Cheng Z
Cancer Lett; 2014 Apr; 346(1):114-21. PubMed ID: 24368190
[TBL] [Abstract][Full Text] [Related]
32. Chronic nickel (II) exposure induces the stemness properties of cancer cells through repressing isocitrate dehydrogenase (IDH1).
Wang L; He S; Xiong Z; Lu J; Lin Y; Jin H; Yang L
Ecotoxicol Environ Saf; 2021 Apr; 213():112031. PubMed ID: 33578097
[TBL] [Abstract][Full Text] [Related]
33. TNFα-induced IDH1 hyperacetylation reprograms redox homeostasis and promotes the chemotherapeutic sensitivity.
Yang H; Zhao X; Liu J; Jin M; Liu X; Yan J; Yao X; Mao X; Li N; Liang B; Xie W; Zhang K; Zhao J; Liu L; Huang G
Oncogene; 2023 Jan; 42(1):35-48. PubMed ID: 36352097
[TBL] [Abstract][Full Text] [Related]
34. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation.
Leonardi R; Subramanian C; Jackowski S; Rock CO
J Biol Chem; 2012 Apr; 287(18):14615-20. PubMed ID: 22442146
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
[TBL] [Abstract][Full Text] [Related]
36. Silibinin exerts anti-cancer activity on human ovarian cancer cells by increasing apoptosis and inhibiting epithelial-mesenchymal transition (EMT).
Maleki N; Yavari N; Ebrahimi M; Faisal Faiz A; Khosh Ravesh R; Sharbati A; Panji M; Lorian K; Gravand A; Abbasi M; Abazari O; Shafiee Mehr M; Eskandari Y
Gene; 2022 May; 823():146275. PubMed ID: 35189245
[TBL] [Abstract][Full Text] [Related]
37. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
[TBL] [Abstract][Full Text] [Related]
38. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
Ohka F; Ito M; Ranjit M; Senga T; Motomura A; Motomura K; Saito K; Kato K; Kato Y; Wakabayashi T; Soga T; Natsume A
Tumour Biol; 2014 Jun; 35(6):5911-20. PubMed ID: 24590270
[TBL] [Abstract][Full Text] [Related]
39. Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer.
Li J; Huang J; Huang F; Jin Q; Zhu H; Wang X; Chen M
Oncotarget; 2016 Nov; 7(45):73638-73650. PubMed ID: 27655638
[TBL] [Abstract][Full Text] [Related]
40. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
